Ionis Pharmaceuticals Stock News

Nisa Investment Advisors LLC lowered its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 19.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,249 shares of the companys stock after selling 1,534 shares during the quarter. Nisa Investment Advisors LLCs holdings in []

Sicart Associates LLC lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 20.9% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 291,254 shares of the companys stock after selling 77,155 shares during the period. Ionis Pharmaceuticals accounts for approximately 2.7% of Sicart Associates LLCs holdings, making []

Ionis (IONS) and AstraZeneca (AZN) are set to have joint development and commercialization rights of eplontersen in the United States. AstraZeneca will have exclusive rights to commercialize it in the

Ionis (IONS) and AstraZeneca (AZN) are set to have joint development and commercialization rights of eplontersen in the United States. AstraZeneca will have exclusive rights to commercialize it in the

The Antisense Oligonucleotide Therapies Market research report provides market forecast information, considering the history of the industry, the future of the industry with respect to what situation it may face, it will grow or it will fail. Inputs of various

The stock price of Ionis Pharmaceuticals Inc (NASDAQ: IONS) increased by over 10% during intraday trading. This is why it happened.

AstraZeneca has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. Eplontersen is a ligand-conjugated antisense investigational medicine currently in Phase III clinical trials for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PN). It is designed to reduce the production of transthyretin (TTR protein) to treat both hereditary and non- Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=282506

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome Acadia Pharmaceuticals Inc. (N

Stocks Soar On Optimism Omicron Is A Dud As Traders Focus On Growing China Stimulus U.S. index futures rallied, led by gains for Nasdaq 100 contracts, amid waning omicron worries and a booster shot of Chinese stimulus lifted world stock markets and oil on Tuesday and left traders offloading safe-haven currencies and bonds for the second day in a row. Emini S&P futures were up 61 point to 4,650.75 or about 120 points higher then where Gartman said "stocks are headed lower" some 24 hours ago. Nasdaq futures were up 1.8% and Dow futures rose 1% in premarket trading. In fact, futures are now just 50 points away from where they were below the Black Friday Omicron panic plunge. The FTSEurofirst 300 index was on track for its first back-to-back run of plus 1% gains since February while Asia saw record bounces from some of China''s biggest firms such as Alibaba which soared by the most since its 2019 listing in Hong Kong, leading a rebound in Chinese tech stocks, as bargain hunters piled in amid improved sentiment following Beijings move to bolster the economy.

LONDON (dpa-AFX) - AstraZeneca Plc. (AZN.L, AZN) Tuesday said it has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. for eplontersen, formerl

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) Tuesday said it has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. for eplontersen, formerly known as IONIS-TTR-LRX. The companies will jointly develop and commercialise eplontersen in the US, while AstraZeneca will develop and commercialise it in

(PLX AI) - AstraZeneca entered into a new global development and commercialization agreement with Ionis Pharmaceuticals for eplontersen. AstraZeneca says the liver-targeted antisense therapy is in

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CARLSBAD, Calif., Dec. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a virtual investor day on Thursday, December 9 th at 11:00 a.m. Eastern Time.

A couple of months back we discussed the decline in the stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, following nega